Yazar "Isikdogan, A." seçeneğine göre listele
Listeleniyor 1 - 6 / 6
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe The changing pattern of risk factors and disease characteristics of breast cancer in Turkey: A cross-sectional study of a Turkish oncology group (BREASTTURK)(Amer Soc Clinical Oncology, 2011) Akbulut, H.; Altundag, M. K.; Saip, P.; Coskun, H. S.; Camci, C.; Ozkan, M.; Paydas, S.; Zengin, N.; Alco, G.; Aliustaoglu, M.; Basaran, G.; Yamac, D.; Yucel, I.; Goker, E.; Yaman, E.; Isikdogan, A.; Ozisik, Y. Y.; Topuz, E.; Ozdogan, M.; Icli, F.Öğe Clinical outcomes among ErbB2+MBC patients treated with lapatinib-capecitabine after trastuzumab progression: Role of early switch to lapatinib (TYCO study).(Amer Assoc Cancer Research, 2012) Abulkhair, O.; Uslu, R.; Sezgin, C.; Bueyuekberber, S.; Darwish, T.; Isikdogan, A.; Gumus, M.; Dane, F.; Sevinc, A.; Halawani, H.; Uncu, D.; Marrero, N.; Tobler, J.; Soares, C.; Landis, S.; Moraes, E.; Gidekel, R.; Santillana, S.; Nunez, P.; Cagnolati, S.; Rodriguez, J. G.Öğe Cost effectiveness of Oncotype DX test in patients with early-stage breast cancer in a middle-income country, Turkey: results of a prospective multicenter study(Churchill Livingstone, 2017) Ozmen, V.; Gokmen, E.; Atasoy, A.; Ozdogan, M.; Guler, N.; Uras, C.; Ok, E.; Demircan, O.; Isikdogan, A.; Saip, P.Öğe First-line anti-EGFR agents (panitumumab or cetuximab) plus chemotherapy in patients with metastatic colorectal cancer: Onco-colon Turkey study subgroup analysis(Elsevier, 2022) Isikdogan, A.; Turk, H.; Bilir, C.; Sendur, M.; Karabulut, B.; Artac, M.; Cicin, I.[No Abstract Available]Öğe Nine versus 52 weeks of adjuvant trastuzumab in early breast cancer: An observational study of the Turkish Oncology Group.(Amer Soc Clinical Oncology, 2011) Icli, F.; Altundag, K.; Coskun, U.; Paydas, S.; Basaran, G.; Saip, P.; Dogu, G. G.; Eralp, Y.; Uslu, R.; Sevinc, A.; Onur, H.; Mandel, N. M.; Sezgin, C.; Altinbas, M.; Guler, N.; Isikdogan, A.; Gokmen, E.; Uygun, K.; Ustuner, Z.; Yaren, A.Öğe Real-life experience with chemotherapy plus biologics in first-line treatment of right-sided, RAS wild-type, metastatic colon cancer: A multicenter Onco-Colon Turkey study(Elsevier, 2021) Arslan, C.; Kefeli, U.; Yildirim, E.; Isikdogan, A.; Karadurmus, N.; Karabulut, B.; Cicin, I.[No Abstract Available]
